These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15373800)

  • 1. Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions.
    Smalley KS; Herlyn M
    J Invest Dermatol; 2004 Oct; 123(4):xvi-xvii. PubMed ID: 15373800
    [No Abstract]   [Full Text] [Related]  

  • 2. BRAF kinase gene V599E mutation in growing melanocytic lesions.
    Loewe R; Kittler H; Fischer G; Faé I; Wolff K; Petzelbauer P
    J Invest Dermatol; 2004 Oct; 123(4):733-6. PubMed ID: 15373778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of the BRAF gene in benign and malignant melanocytic lesions.
    Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA
    J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High BRAF mutation frequency does not characterize all melanocytic tumor types.
    Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
    Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma.
    Mihic-Probst D; Perren A; Schmid S; Saremaslani P; Komminoth P; Heitz PU
    Anticancer Res; 2004; 24(4):2415-8. PubMed ID: 15330192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF point mutations in primary melanoma show different prevalences by subtype.
    Sasaki Y; Niu C; Makino R; Kudo C; Sun C; Watanabe H; Matsunaga J; Takahashi K; Tagami H; Aiba S; Horii A
    J Invest Dermatol; 2004 Jul; 123(1):177-83. PubMed ID: 15191558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic B-RAF(V600E) promotes anchorage-independent survival of human melanocytes.
    Becker TM; Philipsz S; Scurr LL; Fung C; Haferkamp S; Kefford RF; Rizos H
    J Invest Dermatol; 2010 Aug; 130(8):2144-7. PubMed ID: 20445557
    [No Abstract]   [Full Text] [Related]  

  • 9. Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.
    Houben R; Ortmann S; Drasche A; Troppmair J; Herold MJ; Becker JC
    J Invest Dermatol; 2009 Feb; 129(2):406-14. PubMed ID: 18650848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF as a melanoma susceptibility candidate gene?
    Laud K; Kannengiesser C; Avril MF; Chompret A; Stoppa-Lyonnet D; Desjardins L; Eychene A; Demenais F; Lenoir GM; Bressac-de Paillerets B;
    Cancer Res; 2003 Jun; 63(12):3061-5. PubMed ID: 12810628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma.
    Liu W; Kelly JW; Trivett M; Murray WK; Dowling JP; Wolfe R; Mason G; Magee J; Angel C; Dobrovic A; McArthur GA
    J Invest Dermatol; 2007 Apr; 127(4):900-5. PubMed ID: 17159915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Determinants of BRAF mutations in primary melanomas.
    Purdue MP
    J Natl Cancer Inst; 2005 Mar; 97(5):401-2; author reply 402. PubMed ID: 15741578
    [No Abstract]   [Full Text] [Related]  

  • 13. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
    Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
    J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
    Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
    Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.
    Takata M; Murata H; Saida T
    Pigment Cell Melanoma Res; 2010 Feb; 23(1):64-71. PubMed ID: 19788535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF mutations are common somatic events in melanocytic nevi.
    Kumar R; Angelini S; Snellman E; Hemminki K
    J Invest Dermatol; 2004 Feb; 122(2):342-8. PubMed ID: 15009715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of NRAS and BRAF mutations in cutaneous melanoma.
    Rosso R; Romagosa Y; Kirsner RS
    J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
    Deichmann M; Thome M; Benner A; Näher H
    Oncology; 2004; 66(5):411-9. PubMed ID: 15331929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.